RxSight, Inc. (NASDAQ:RXST) CEO Sells $2,406,000.00 in Stock

RxSight, Inc. (NASDAQ:RXST) CEO Ronald M. Md Kurtz sold 40,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the sale, the chief executive officer now owns 764,610 shares of the company’s stock, valued at approximately $45,991,291.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

RxSight Stock Up 1.9 %

Shares of NASDAQ RXST opened at $62.84 on Tuesday. The business has a 50-day simple moving average of $52.73 and a two-hundred day simple moving average of $43.06. RxSight, Inc. has a 52 week low of $18.35 and a 52 week high of $64.92. The company has a market cap of $2.32 billion, a P/E ratio of -43.94 and a beta of 1.21.

RxSight (NASDAQ:RXST) last posted its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. The business had revenue of $28.58 million for the quarter, compared to analyst estimates of $28.60 million. Equities research analysts anticipate that RxSight, Inc. will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RXST shares. JPMorgan Chase & Co. raised their price target on shares of RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Oppenheimer upped their price target on RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of RxSight in a research note on Thursday, April 11th. Finally, Stifel Nicolaus boosted their price objective on RxSight from $64.00 to $68.00 and gave the company a “buy” rating in a research note on Monday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $50.13.

Institutional Investors Weigh In On RxSight

Several large investors have recently added to or reduced their stakes in RXST. Quantbot Technologies LP raised its holdings in shares of RxSight by 8.4% in the 1st quarter. Quantbot Technologies LP now owns 53,686 shares of the company’s stock valued at $2,769,000 after acquiring an additional 4,167 shares in the last quarter. Larson Financial Group LLC purchased a new stake in RxSight in the first quarter valued at approximately $51,000. GSA Capital Partners LLP bought a new stake in RxSight during the first quarter valued at approximately $1,929,000. RiverPark Advisors LLC grew its stake in RxSight by 361.4% in the 1st quarter. RiverPark Advisors LLC now owns 3,082 shares of the company’s stock worth $159,000 after buying an additional 2,414 shares in the last quarter. Finally, FORA Capital LLC increased its holdings in shares of RxSight by 5.6% in the 1st quarter. FORA Capital LLC now owns 11,695 shares of the company’s stock worth $603,000 after buying an additional 622 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.